News Release - June 24, 2008

European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naïve HIV-1 Infected Adults

Source: Bristol-Myers Squibb

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.